Gatifloxacin

Class: Fluoroquinolone

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Gatifloxacin was developed as a broad spectrum antibiotic for a number of different infections including STIs, RTIs and eye disorders (3)
Description:	Hori S, Kanemitsu K, Shimada J. Inhibitory activity of AM-1155, a newly synthesized quinolone, on gamma aminobutyric acid receptor binding. 32nd-ICAAC 1992;277
Institute where first reported:	Allergan, UK; Kyorin Pharmaceutical, Japan; Senju Pharmaceutical, Japan; AbbVie
Year first mentioned:	1992
Highest developmental phase:	Approved by FDA in 2010
Development status:	Approved
Reason Dropped:	Other formulations discontinued from market due to hypo- and hyper- glycaemia (2)

Chemical structure(s):
Canonical SMILES:	CC1CN(CCN1)C2=C(C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(=O)O)OC
Isomeric SMILES:	CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
InChI:	InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
InChI Key:	XUBOMFCQGDBHNK-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/5379

External links:
Guide to Pharmacology:	gatifloxacin
Main Source:	https://journals.asm.org/doi/10.1128/aac.36.10.2108
Citations:	http://adisinsight.springer.com/drugs/800001673 Http://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/fluoroquinolones